4 European Projects Found
Searched on 125080 European Projects
FINISHED
European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)
Start date: Oct 1, 2012, End date: Sep 30, 2017,
EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Read Project
29
Partners Participants
FINISHED
Profiling Responders In Antibody Therapies (PRIAT)
Start date: Nov 1, 2012, End date: Oct 31, 2014,
...tastatic melanoma and rheumatoid arthritis respectively at multiple clinical centres including Graz and Tübingen.Building on the strong background in proteomics biomarker discovery of ETH Zurich and Philochem, an innovative methodology (“HLA-peptidome analysis”) will be utilized for gaining information on the immune response in animal models and patients which receive antibody treatments. This met ...
Read Project
8
Partners Participants
FINISHED
European Consortium for Anticancer Antibody Development (EUCAAD)
Start date: May 1, 2008, End date: Apr 30, 2012,
Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. R ...
Read Project
9
Partners Participants
FINISHED
ANTIBODY DERIVATIVES AS MOLECULAR AGENTS FOR NEOPLASTIC TARGETING (ADAMANT)
Start date: Apr 1, 2008, End date: Mar 31, 2011,
"The selective delivery of bioactive agents (cytotoxics, radionuclides, cytokines) at the tumor site, while sparing normal tissues, represents one of the most promising avenues for the development of anticancer therapies with unprecedented efficacy and tolerability. Monoclonal antibodies represent the preferred vehicle for the targeted delivery of bioactive agents to cancer sites, as they can disp ...
Read Project
